Form 4: Dyne Therapeutics Director Lubner Acquires Stock Options
SEC Form 4 Filing
Director David Charles Lubner acquired stock options in Dyne Therapeutics, Inc. on May 22, 2024.
Summary
- David Charles Lubner, a director of Dyne Therapeutics, Inc., acquired stock options on May 22, 2024.
- The transaction involved the acquisition of 25,133 stock options with an exercise price of $31.53.
- These options vest fully on the earlier of May 22, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service.
- Following the transaction, Lubner directly owns 25,133 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors, offering insights into their confidence in the company's future performance.
Stakeholder Impact
- The acquisition of stock options by a director can signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of stock option grant |
| 05/22/2025 | Earliest possible vesting date for the stock options |
| 05/21/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.